Jilin Sinoscience Technology Co. LTD
Jilin Sinoscience Technology Co. LTD is a high & new technology enterprise, specializing in research, production, sales, and service of clinical diagnostics products. We are established in Changchun in 2021.
Our main products are In vitro diagnostics reagent and instruments. We have more than 70 items of reagent in IVD field, and continue to develop Auto-Chemistry Analyzer, urinalysis products and so on. We are committed to be one of the best suppliers in IVD industry, with advanced technology, top quality and offer various series products.
At the same time, we also want to become a third-party medical testing center, which provide regional medical testing service, equipping with self-developed regional LIS system, modern disinfection center, Cold Chain Logistics system, Cloud Platform and other supporting system.
Aim
Technological
innovation, benefiting human beings, chasing our dreams, constructing China
together!
It is our service aim. Sinoscience has a
professional service team and high - effective service awareness, we will provide our customers with dedicated technology service, and we will be one of the
professional suppliers with perfect service system.
Vision
Sinoscience are committed to be a supplier
with medical testing integrated System in China and provide customers
the laboratory whole solutions. We will launch a series of high-tech products
and make a contribution to IVD field development and human health.
Mission
Technological
innovation, building Chinese dream!
Sinoscience constantly
bring forth new ideas and develop high quality products with advanced
technology and perfect system, to help to fulfill Chinese dream.
Values
Professional service, customer first
Sinoscience offers the best service as a high-tech enterprise. We focus
on the human health, and create hope for lives.
Jilin Sinoscience Technology Co. LTD
Jilin Sinoscience Technology Co. LTD is a high & new technology enterprise, specializing in research, production, sales, and service of clinical diagnostics products. We are established in Changchun in 2021.
Our main products are In vitro diagnostics reagent and instruments. We have more than 70 items of reagent in IVD field, and continue to develop Auto-Chemistry Analyzer, urinalysis products and so on. We are committed to be one of the best suppliers in IVD industry, with advanced technology, top quality and offer various series products.
At the same time, we also want to become a third-party medical testing center, which provide regional medical testing service, equipping with self-developed regional LIS system, modern disinfection center, Cold Chain Logistics system, Cloud Platform and other supporting system.
Aim
Technological
innovation, benefiting human beings, chasing our dreams, constructing China
together!
It is our service aim. Sinoscience has a
professional service team and high - effective service awareness, we will provide our customers with dedicated technology service, and we will be one of the
professional suppliers with perfect service system.
Vision
Sinoscience are committed to be a supplier
with medical testing integrated System in China and provide customers
the laboratory whole solutions. We will launch a series of high-tech products
and make a contribution to IVD field development and human health.
Mission
Technological
innovation, building Chinese dream!
Sinoscience constantly
bring forth new ideas and develop high quality products with advanced
technology and perfect system, to help to fulfill Chinese dream.
Values
Professional service, customer first
Sinoscience offers the best service as a high-tech enterprise. We focus
on the human health, and create hope for lives.
WuXi AppTec (stock code: 603259.SH/2359.HK) provides integrated, end-to-end new drug research and development and production services to the global biopharmaceutical industry, and has operating bases in Asia, Europe, North America and other places. WuXi AppTec continuously lowers R&D threshold through its unique "CRDMO" and "CTDMO" business models, helps customers improve R&D efficiency and brings more breakthrough treatment plans to patients. Its service scope covers chemical drug research and development, production, and biology. Research, preclinical testing and clinical trial research and development, cell and gene therapy research and development, testing and production and other fields. In 2022, WuXi AppTec was rated as ESG (Environmental, Social and Governance) AA by MSCI. At present, the company's empowerment platform is carrying R&D and innovative projects from more than 5,950 partners from more than 30 countries around the world, and is committed to bringing more new and good drugs to patients around the world, so as to achieve "making the world without any difficulties" as soon as possible The vision of medicine, difficult to cure diseases.
WuXi AppTec Co., Ltd.
WuXi AppTec (stock code: 603259.SH/2359.HK) provides integrated, end-to-end new drug research and development and production services to the global biopharmaceutical industry, and has operating bases in Asia, Europe, North America and other places. WuXi AppTec continuously lowers R&D threshold through its unique "CRDMO" and "CTDMO" business models, helps customers improve R&D efficiency and brings more breakthrough treatment plans to patients. Its service scope covers chemical drug research and development, production, and biology. Research, preclinical testing and clinical trial research and development, cell and gene therapy research and development, testing and production and other fields. In 2022, WuXi AppTec was rated as ESG (Environmental, Social and Governance) AA by MSCI. At present, the company's empowerment platform is carrying R&D and innovative projects from more than 5,950 partners from more than 30 countries around the world, and is committed to bringing more new and good drugs to patients around the world, so as to achieve "making the world without any difficulties" as soon as possible The vision of medicine, difficult to cure diseases.
Pharmaron Beijing Co., Ltd.
Kanglong Huacheng (stock code: 300759.SZ/3759.HK) is an international leading life science research and development service company. Since its establishment in 2004, Kanglong Huacheng has been committed to its talent training and facility construction, creating a running drug discovery, preclinical and clinical development for the research and development of multi-therapeutic drugs including small molecules, large molecules, and cell and gene therapy drugs. Develop a full-process R&D and production service system. Kanglong Huacheng operates in China, the United States and the United Kingdom, with more than 20,000 employees, providing R&D solutions to partners in North America, Europe, Japan and China and maintaining good cooperative relationships with them.
Pharmaron Beijing Co., Ltd.
Kanglong Huacheng (stock code: 300759.SZ/3759.HK) is an international leading life science research and development service company. Since its establishment in 2004, Kanglong Huacheng has been committed to its talent training and facility construction, creating a running drug discovery, preclinical and clinical development for the research and development of multi-therapeutic drugs including small molecules, large molecules, and cell and gene therapy drugs. Develop a full-process R&D and production service system. Kanglong Huacheng operates in China, the United States and the United Kingdom, with more than 20,000 employees, providing R&D solutions to partners in North America, Europe, Japan and China and maintaining good cooperative relationships with them.
IQVIA Medical Science & Technology (Shanghai) Co., Ltd.
IQVIA is a global leader in the healthcare industry, using data, technology, statistical analysis and human intelligence to help customers promote the progress of healthcare and human health. Work together to create a more modern, feasible and efficient medical system, transform commercial operations with innovative solutions, and benefit patients faster by benefiting medical results.
IQVIA Medical Science & Technology (Shanghai) Co., Ltd.
IQVIA is a global leader in the healthcare industry, using data, technology, statistical analysis and human intelligence to help customers promote the progress of healthcare and human health. Work together to create a more modern, feasible and efficient medical system, transform commercial operations with innovative solutions, and benefit patients faster by benefiting medical results.
Asymchem Laboratories (Tianjin) Co., Ltd.
Kelleying Pharmaceutical Group (stock code: 002821.SZ/6821.HK) is a well-known CDMO company that provides high-quality research and development and production one-stop services for global new drugs. Taking it as our mission to accelerate the launch of new drugs and extend the quality of life, relying on continuous technological innovation, we provide domestic and foreign pharmaceutical companies and biotechnology companies with one-stop CMC services for the entire life cycle of the drug to accelerate the development and application of new drugs. Currently, it has 8 major R&D and production bases around the world, more than 20 companies, and more than 9,800 employees. The business scope covers the early stage of clinical practice to commercialization, including the research and development of advanced intermediates, raw materials, preparations, etc., and cGMP production, as well as clinical research services. Through strategic cooperation and business expansion, we will gradually build an integrated service ecosystem for innovative drugs and become a partner in the research and development and production of new drugs in the world.
Asymchem Laboratories (Tianjin) Co., Ltd.
Kelleying Pharmaceutical Group (stock code: 002821.SZ/6821.HK) is a well-known CDMO company that provides high-quality research and development and production one-stop services for global new drugs. Taking it as our mission to accelerate the launch of new drugs and extend the quality of life, relying on continuous technological innovation, we provide domestic and foreign pharmaceutical companies and biotechnology companies with one-stop CMC services for the entire life cycle of the drug to accelerate the development and application of new drugs. Currently, it has 8 major R&D and production bases around the world, more than 20 companies, and more than 9,800 employees. The business scope covers the early stage of clinical practice to commercialization, including the research and development of advanced intermediates, raw materials, preparations, etc., and cGMP production, as well as clinical research services. Through strategic cooperation and business expansion, we will gradually build an integrated service ecosystem for innovative drugs and become a partner in the research and development and production of new drugs in the world.
Hangzhou DIAN Biotechnology Co., Ltd.
DIAN Diagnostic Group Co., Ltd., founded in 1996 and was listed in 2011 (China stock code: 300244), is committed to providing integrated solutions for medical diagnostics, with third-party diagnostic services as its core business.
Hangzhou DIAN Biotechnology Co., Ltd. (GENEDIAN), holding subsidiary of DIAN Diagnostics, is a high-tech IVD enterprise providing one-stop solutions of "reagent + instrument+ digital intelligent system" for clinical and laboratory in molecular diagnostic and pathological diagnostic area.
DIAN Biotech is devoted to in-house R&D, manufacture, international sales and technical service. Its factory is ISO 13485 certified and complies to GMP standards, and it is equipped with 11,000 m² factory size for production, over 11 automated production lines to ensure annual production capacity up to 600 million tests.
Served over 17,000 medical institutions all over China, DIAN Biotech is exploring international market with its digital and Ai-assisted pathology diagnostic solutions for worldwide health concern.
Hangzhou DIAN Biotechnology Co., Ltd.
DIAN Diagnostic Group Co., Ltd., founded in 1996 and was listed in 2011 (China stock code: 300244), is committed to providing integrated solutions for medical diagnostics, with third-party diagnostic services as its core business.
Hangzhou DIAN Biotechnology Co., Ltd. (GENEDIAN), holding subsidiary of DIAN Diagnostics, is a high-tech IVD enterprise providing one-stop solutions of "reagent + instrument+ digital intelligent system" for clinical and laboratory in molecular diagnostic and pathological diagnostic area.
DIAN Biotech is devoted to in-house R&D, manufacture, international sales and technical service. Its factory is ISO 13485 certified and complies to GMP standards, and it is equipped with 11,000 m² factory size for production, over 11 automated production lines to ensure annual production capacity up to 600 million tests.
Served over 17,000 medical institutions all over China, DIAN Biotech is exploring international market with its digital and Ai-assisted pathology diagnostic solutions for worldwide health concern.
Wisdom Medical Technology Co., Ltd.
Ruizhi Pharmaceutical Technology Co., Ltd. (stock abbreviation: Ruizhi Pharmaceutical, stock code: 300149) is driven by biotechnology innovation and focuses on the fields of pharmaceutical research and development, production service outsourcing and microecological medical care. Ruizhi Pharmaceutical provides integrated services covering the stages of biopharmaceuticals and chemical drugs from early drug discovery to drug development and large-scale production, and realizes the standardization and precision of microecological medical care. and human microecology health management. Ruizhi Pharmaceutical is committed to becoming the world's advanced CRO&CDMO partner and a global full-life cycle integrated solution provider for pharmaceutical innovation. Ruizhi Pharmaceutical has 5 national high-tech enterprises and cultivates a professional scientific research service team, including more than 2,000 scientific researchers. The headquarters is located in Shanghai, China, and has established research institutes, laboratories, production bases and operating entities in the United States, Denmark, Hong Kong, Shanghai, Guangzhou, Chengdu, Jiangmen and other places. The sales service network covers five continents around the world. Ruizhi Pharmaceutical adheres to the development concept of "technology-based and technology-first" and the corporate vision of "becoming a global advanced pharmaceutical and health innovation service enterprise", helps China's pharmaceutical industry innovation and upgrading, and continues to empower the innovation of the global pharmaceutical and health industry, and for the world. Innovative drug services continue to provide the driving force for innovative R&D.
Wisdom Medical Technology Co., Ltd.
Ruizhi Pharmaceutical Technology Co., Ltd. (stock abbreviation: Ruizhi Pharmaceutical, stock code: 300149) is driven by biotechnology innovation and focuses on the fields of pharmaceutical research and development, production service outsourcing and microecological medical care. Ruizhi Pharmaceutical provides integrated services covering the stages of biopharmaceuticals and chemical drugs from early drug discovery to drug development and large-scale production, and realizes the standardization and precision of microecological medical care. and human microecology health management. Ruizhi Pharmaceutical is committed to becoming the world's advanced CRO&CDMO partner and a global full-life cycle integrated solution provider for pharmaceutical innovation. Ruizhi Pharmaceutical has 5 national high-tech enterprises and cultivates a professional scientific research service team, including more than 2,000 scientific researchers. The headquarters is located in Shanghai, China, and has established research institutes, laboratories, production bases and operating entities in the United States, Denmark, Hong Kong, Shanghai, Guangzhou, Chengdu, Jiangmen and other places. The sales service network covers five continents around the world. Ruizhi Pharmaceutical adheres to the development concept of "technology-based and technology-first" and the corporate vision of "becoming a global advanced pharmaceutical and health innovation service enterprise", helps China's pharmaceutical industry innovation and upgrading, and continues to empower the innovation of the global pharmaceutical and health industry, and for the world. Innovative drug services continue to provide the driving force for innovative R&D.
Guangzhou Sonostar Technologies Co., Limited
Sonostar Technologies Co., Limited is specialized in R&D, production and sales. We provide state-of-the-art medical equipment ranging from ultrasound equipment to patient monitoring, ophthalmic, dental and respirator equipment.
We insist on making modern medical technology affordable without compromising quality.
We have extensive experience offering ODM and OEM services for many domestic and overseas enterprises, and we began entering international markets in recent years.
Our motto and aim is "New Tech, New Life". And we mean it. As a company, we strive to popularize and utilize advanced technology, thus benefitting patients, their families and medical professionals alike.
Our friendly costumer service is ready to help in the case of any questions or concerns.
We warmly welcome potential business partners and the medical community to join hands with us in our endeavour to make the world a better place.
Our main products:Ultrasound Scanner,Probe Type Ultrasound Scanner,B/W Ultrasound Scanner ,Vet Ultrasound Scanner, Ophthalmology Scanner ect.
Guangzhou Sonostar Technologies Co., Limited
Sonostar Technologies Co., Limited is specialized in R&D, production and sales. We provide state-of-the-art medical equipment ranging from ultrasound equipment to patient monitoring, ophthalmic, dental and respirator equipment.
We insist on making modern medical technology affordable without compromising quality.
We have extensive experience offering ODM and OEM services for many domestic and overseas enterprises, and we began entering international markets in recent years.
Our motto and aim is "New Tech, New Life". And we mean it. As a company, we strive to popularize and utilize advanced technology, thus benefitting patients, their families and medical professionals alike.
Our friendly costumer service is ready to help in the case of any questions or concerns.
We warmly welcome potential business partners and the medical community to join hands with us in our endeavour to make the world a better place.
Our main products:Ultrasound Scanner,Probe Type Ultrasound Scanner,B/W Ultrasound Scanner ,Vet Ultrasound Scanner, Ophthalmology Scanner ect.
Labcorp Drug Development (Shanghai) Co., Ltd.
Leiboco is a world-leading life sciences company that provides doctors, hospitals, pharmaceutical companies, researchers and patients with vital information to help them make clear and confident decisions. Relying on experience and capabilities in the fields of diagnosis and pharmaceutical research and development, Leiboke has insight into the future and accelerated innovation to improve health and life. When you need information to make clear and confident decisions, LeBoc will be your source of trust. Headquartered in Burlington, North Carolina, USA, Leiboco has more than 65,000 employees worldwide and serves customers in more than 100 countries and regions. The company's stock code on the New York Stock Exchange is LH.
Labcorp Drug Development (Shanghai) Co., Ltd.
Leiboco is a world-leading life sciences company that provides doctors, hospitals, pharmaceutical companies, researchers and patients with vital information to help them make clear and confident decisions. Relying on experience and capabilities in the fields of diagnosis and pharmaceutical research and development, Leiboke has insight into the future and accelerated innovation to improve health and life. When you need information to make clear and confident decisions, LeBoc will be your source of trust. Headquartered in Burlington, North Carolina, USA, Leiboco has more than 65,000 employees worldwide and serves customers in more than 100 countries and regions. The company's stock code on the New York Stock Exchange is LH.
Hangzhou Tigermed Consulting Co., Ltd.
Tiger Pharmaceuticals (stock code: 300347.SZ/3347.HK) is a contract research organization (CRO) focusing on providing professional services for clinical trials for new drug research and development, providing comprehensive clinical research for global pharmaceutical and medical device innovation companies. Services and solutions reduce R&D risks, shorten R&D cycles, save R&D funds, promote the marketization of products, and allow patients to use newer and better medical and medical products as soon as possible. Tiger Pharmaceutical has established an integrated service platform covering the entire clinical research industry chain, serving the entire life cycle of drug and medical device product development, mainly including registration and regulatory affairs, clinical trials and clinical operations, data management and statistical analysis, Integrated clinical development technical services, medical devices and in vitro diagnostic reagents, post-market research and real-world research, etc. Tiger Pharmaceuticals has also been a pioneer in global expansion of China's clinical CROs, and is currently operating in the Asia-Pacific region, North America and Europe. As of July 2021, Tiger Pharmaceutical has deployed Tiger employees in 39 countries around the world and established 17 overseas branches and offices. Since its establishment in 2004, Tiger Pharmaceutical has built a complete integrated and multi-faceted R&D service platform for clinical research of drugs and medical devices through the extension of its industrial chain and the construction of regional service capabilities. At the same time, Tiger Pharmaceutical has also continued to promote international expansion through investment, mergers and acquisitions, self-built teams, etc.
Hangzhou Tigermed Consulting Co., Ltd.
Tiger Pharmaceuticals (stock code: 300347.SZ/3347.HK) is a contract research organization (CRO) focusing on providing professional services for clinical trials for new drug research and development, providing comprehensive clinical research for global pharmaceutical and medical device innovation companies. Services and solutions reduce R&D risks, shorten R&D cycles, save R&D funds, promote the marketization of products, and allow patients to use newer and better medical and medical products as soon as possible. Tiger Pharmaceutical has established an integrated service platform covering the entire clinical research industry chain, serving the entire life cycle of drug and medical device product development, mainly including registration and regulatory affairs, clinical trials and clinical operations, data management and statistical analysis, Integrated clinical development technical services, medical devices and in vitro diagnostic reagents, post-market research and real-world research, etc. Tiger Pharmaceuticals has also been a pioneer in global expansion of China's clinical CROs, and is currently operating in the Asia-Pacific region, North America and Europe. As of July 2021, Tiger Pharmaceutical has deployed Tiger employees in 39 countries around the world and established 17 overseas branches and offices. Since its establishment in 2004, Tiger Pharmaceutical has built a complete integrated and multi-faceted R&D service platform for clinical research of drugs and medical devices through the extension of its industrial chain and the construction of regional service capabilities. At the same time, Tiger Pharmaceutical has also continued to promote international expansion through investment, mergers and acquisitions, self-built teams, etc.
Beijing Joinn Laboratories Co., Ltd.
Zhaoyan Pharmaceuticals (stock code: 603127.SH/6127.HK), founded in 1995, is a professional drug research and development service outsourcing enterprise (CRO). It is headquartered in Beijing, in Beijing, Suzhou, Chongqing, Guangzhou, Wuxi and Wuzhou. , Nanning, Yunnan, Shanghai, California and Boston, USA, have subsidiaries, and currently have a professional and technical team of more than 2,500 people. Zhaoyan Pharmaceutical has established a quality management system that complies with international standards (CNAS/ILAC-MRA certification), and has the GLP qualifications of China NMPA, the US FDA, the Japanese PMDA, the South Korean MFDS and the OECD OECD, as well as the international AAALAC (animal welfare) certification qualifications. , evaluation data meet global drug registration requirements. It can provide customers with non-clinical pharmacological and toxicological research and evaluation, especially non-clinical safety evaluation, clinical trials and pharmacological alerts, and can also provide services such as veterinary drugs, pesticides and medical device evaluation. Zhaoyan New Drug's main bases of non-clinical evaluation business in China are Zhaoyan (Beijing) and Zhaoyan (Suzhou), and the two places have 73,200m2 animal experimental facilities that meet international standards; Zhaoyan (Guangzhou) and Zhaoyan (Chongqing) It is also under construction and is scheduled to be put into operation in 2023. Zhaoyan New Drug is one of the institutions in China that are currently engaged in non-clinical safety evaluation services. It can provide customers with personalized solutions for drugs, medical devices, veterinary drugs, pesticides and other new chemicals, drug screening, and pharmacodynamic research. , pharmacokinetic research, safety evaluation and other services. Zhaoyan New Drug has always adhered to the tenet of "service drug innovation, focusing on safety evaluation and monitoring of the entire life cycle of the drug", and is committed to providing global drug research and development services and solutions across the entire life cycle, ensuring the safety of patients' medication, and caring for humans. healthy!
Beijing Joinn Laboratories Co., Ltd.
Zhaoyan Pharmaceuticals (stock code: 603127.SH/6127.HK), founded in 1995, is a professional drug research and development service outsourcing enterprise (CRO). It is headquartered in Beijing, in Beijing, Suzhou, Chongqing, Guangzhou, Wuxi and Wuzhou. , Nanning, Yunnan, Shanghai, California and Boston, USA, have subsidiaries, and currently have a professional and technical team of more than 2,500 people. Zhaoyan Pharmaceutical has established a quality management system that complies with international standards (CNAS/ILAC-MRA certification), and has the GLP qualifications of China NMPA, the US FDA, the Japanese PMDA, the South Korean MFDS and the OECD OECD, as well as the international AAALAC (animal welfare) certification qualifications. , evaluation data meet global drug registration requirements. It can provide customers with non-clinical pharmacological and toxicological research and evaluation, especially non-clinical safety evaluation, clinical trials and pharmacological alerts, and can also provide services such as veterinary drugs, pesticides and medical device evaluation. Zhaoyan New Drug's main bases of non-clinical evaluation business in China are Zhaoyan (Beijing) and Zhaoyan (Suzhou), and the two places have 73,200m2 animal experimental facilities that meet international standards; Zhaoyan (Guangzhou) and Zhaoyan (Chongqing) It is also under construction and is scheduled to be put into operation in 2023. Zhaoyan New Drug is one of the institutions in China that are currently engaged in non-clinical safety evaluation services. It can provide customers with personalized solutions for drugs, medical devices, veterinary drugs, pesticides and other new chemicals, drug screening, and pharmacodynamic research. , pharmacokinetic research, safety evaluation and other services. Zhaoyan New Drug has always adhered to the tenet of "service drug innovation, focusing on safety evaluation and monitoring of the entire life cycle of the drug", and is committed to providing global drug research and development services and solutions across the entire life cycle, ensuring the safety of patients' medication, and caring for humans. healthy!
QuintilesIMS Holdings, Inc.
A leading integrated healthcare services provider offering information and technology solutions.
QuintilesIMS Holdings, Inc.
A leading integrated healthcare services provider offering information and technology solutions.
INC Research Holdings, Inc.
A global contract research organization specializing in clinical development and commercialization services.
INC Research Holdings, Inc.
A global contract research organization specializing in clinical development and commercialization services.
Chiltern International Ltd.
A global contract research organization offering clinical development and biometrics services.
Chiltern International Ltd.
A global contract research organization offering clinical development and biometrics services.
PRA Health Sciences, Inc.
A global contract research organization delivering innovative drug development solutions.
PRA Health Sciences, Inc.
A global contract research organization delivering innovative drug development solutions.
A drug development services company offering preclinical, clinical, and commercialization support.
Covance Inc.
A drug development services company offering preclinical, clinical, and commercialization support.
Charles River Laboratories International, Inc.
A leading provider of essential products and services to accelerate drug discovery and development.
Charles River Laboratories International, Inc.
A leading provider of essential products and services to accelerate drug discovery and development.
A biopharmaceutical solutions organization integrating clinical and commercial capabilities to accelerate customer success.
Syneos Health, Inc.
A biopharmaceutical solutions organization integrating clinical and commercial capabilities to accelerate customer success.
Pharmaceutical Product Development, LLC
A global contract research organization providing drug development, laboratory, and lifecycle management services.
Pharmaceutical Product Development, LLC
A global contract research organization providing drug development, laboratory, and lifecycle management services.
Parexel International Corporation
A biopharmaceutical services company specializing in clinical research, consulting, and market access solutions.
Parexel International Corporation
A biopharmaceutical services company specializing in clinical research, consulting, and market access solutions.
